NICE (Multiple) Technology Appraisal Guidance No 160
NICE (Multiple) Technology Appraisal Guidance No 160 –
Alendronate, etidronate, risedronate, raloxifene
and strontium ranelate for the primary prevention of osteoporotic
fragility fractures in postmenopausal women.
Web reference for appraisal and other related
documents: http://www.nice.org.uk/guidance/TA160
NHSScotland should note that:
1. No important differences were identified for this NICE
appraisal and NHS Quality Improvement Scotland advises that the
recommendations are as valid for Scotland as for England and
Wales.
2. NHSScotland should take account of the NICE appraisals and
this NHS Quality Improvement Scotland email in its planning,
funding and provision of services to ensure that recommended drugs
or treatments are made available to meet clinical need.
3. NHS Quality Improvement Scotland advice represents the
evidence-based view of NHS Quality Improvement Scotland.
4. This advice does not override or replace the individual
responsibility of health professionals to make appropriate
decisions in the circumstances of their individual patients, in
consultation with the patient and/or guardian or carer.
5. No other publications on the NICE appraisals will be issued
by NHS Quality Improvement Scotland.
6. Copies of the NICE appraisals can be downloaded from
http://www.nice.org.uk. Tools developed by NICE to help
organisations to implement this appraisal and an easy to read
summary of the appraisal, called "understanding NICE guidance" to
provide information for patients and the public, will be available
on the NICE website shortly.
7. Hard copies of the NICE appraisals are available from NHS
Quality Improvement Scotland (contact Hana Bystronova, tel 0131 623
4287 or email hana.bystronova@nhs.net) and
all NICE appraisals and NHS Quality Improvement Scotland advice are
available on the NHS Quality Improvement Scotland website
(http://www.nhshealthquality.org/).
Published Date: 22 October 2008
